Prescribers give thumbs up to Biotie/Lundbeck's Selincro
This article was originally published in Scrip
Executive Summary
Selincro (nalmefene), the alcohol-dependence drug licensed to Lundbeck from Finnish firm Biotie, is going down well with prescribers, says Andreas Eggert, Lundbeck's senior vice-president of global product strategy & portfolio development. as the company prepares for its imminent launch in in the first markets where it has won reimbursement: the Netherlands and Denmark .
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.